| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
John B Rhodes last filed a Form 4 in May 2020, as Director at TNXP. John B Rhodes's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 23,470 shares of TNXP. Net of sales, the TNXP filings show accumulation of 32,500 shares.
John B Rhodes has 7 Form 4 filings on record from February 2016 to May 2020, all as Director at Tonix Pharmaceuticals (TNXP), 2016–2020.
The 10 reported transactions were 4 option or other derivative awards, 3 open-market purchases and 3 option exercises.
Counted by filing, the open-market trades come to 1 purchase worth about $25K and no sales.
The only open-market purchase was 7,500 shares of TNXP at an average $3.33 on June 1, 2018, about $25K.
Shares as reported in the last Form 4 for each company; the most recent is from May 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.